

# EMEA (Europe, Middle East and Africa) Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017

<https://marketpublishers.com/r/E415DA13AAAPEN.html>

Date: October 2017

Pages: 113

Price: US\$ 4,000.00 (Single User License)

ID: E415DA13AAAPEN

## Abstracts

In this report, the EMEA Benign Prostatic Hyperplasia (BPH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (MT), revenue (Million USD), market share and growth rate of Benign Prostatic Hyperplasia (BPH) Drugs for these regions, from 2012 to 2022 (forecast)

Europe: Germany, France, UK, Russia, Italy and Benelux;

Middle East: Saudi Arabia, Israel, UAE and Iran;

Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Benign Prostatic Hyperplasia (BPH) Drugs market competition by top manufacturers/players, with Benign Prostatic Hyperplasia (BPH) Drugs sales volume (MT), price (USD/Kg), revenue (Million USD) and market share for each manufacturer/player; the top players including

Astellas Pharma

Eli Lilly

GlaxoSmithKline

Sanofi

ADC Therapeutics

Advaxis

Agennix

ANI Pharmaceuticals

BHR Pharma

Bristol-Myers Squibb

Boehringer Ingelheim

Dendreo

Endo Pharmaceuticals

On the basis of product, this report displays the sales volume (MT), revenue (Million USD), product price (USD/Kg), market share and growth rate of each type, primarily split into

Alpha-blocker

Phosphodiesterase type-5 inhibitors

5-alpha-Reductase inhibitors

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (MT), market share and growth rate of Benign Prostatic Hyperplasia (BPH) Drugs for each application, including

Clinical medicine

Scientific research

Others

## Contents

EMEA (Europe, Middle East and Africa) Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017

### **1 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS OVERVIEW**

1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs

1.2 Classification of Benign Prostatic Hyperplasia (BPH) Drugs

1.2.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Sales) Comparison by Type (2012-2022)

1.2.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016

1.2.3 Alpha-blocker

1.2.4 Phosphodiesterase type-5 inhibitors

1.2.5 5-alpha-Reductase inhibitors

1.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market by Application/End Users

1.3.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022)

1.3.2 Clinical medicine

1.3.3 Scientific research

1.3.4 Others

1.4 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market by Region

1.4.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Value) Comparison by Region (2012-2022)

1.4.2 Europe Status and Prospect (2012-2022)

1.4.3 Middle East Status and Prospect (2012-2022)

1.4.4 Africa Status and Prospect (2012-2022)

1.5 EMEA Market Size (Value and Volume) of Benign Prostatic Hyperplasia (BPH) Drugs (2012-2022)

1.5.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2022)

1.5.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2022)

### **2 EMEA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION**

2.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by

## Players/Manufacturers

2.1.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share of Major Players (2012-2017)

2.1.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Share by Players (2012-2017)

2.1.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Players (2012-2017)

2.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs (Volume and Value) by Type/Product Category

2.2.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (2012-2017)

2.2.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2012-2017)

2.2.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2012-2017)

2.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs (Volume) by Application

2.4 EMEA Benign Prostatic Hyperplasia (BPH) Drugs (Volume and Value) by Region

2.4.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Region (2012-2017)

2.4.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Region (2012-2017)

2.4.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Region (2012-2017)

## **3 EUROPE BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION**

3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2012-2017)

3.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2012-2017)

3.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2017)

3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type

3.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Application

3.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Value (Revenue) by Countries

3.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Countries (2012-2017)

3.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2012-2017)

3.4.3 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

3.4.4 France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

3.4.5 UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

3.4.6 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

3.4.7 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

3.4.8 Benelux Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

#### **4 MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION**

4.1 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2012-2017)

4.1.1 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2012-2017)

4.1.2 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2017)

4.2 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type

4.3 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Application

4.4 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Value (Revenue) by Countries

4.4.1 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Countries (2012-2017)

4.4.2 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2012-2017)

4.4.3 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

4.4.4 Israel Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

4.4.5 UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate

(2012-2017)

4.4.6 Iran Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate

(2012-2017)

## **5 AFRICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION**

5.1 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2012-2017)

5.1.1 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2012-2017)

5.1.2 Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2017)

5.2 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type

5.3 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Application

5.4 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Value (Revenue) by Countries

5.4.1 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Countries (2012-2017)

5.4.2 Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2012-2017)

5.4.3 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

5.4.4 Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

5.4.5 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

5.4.6 Algeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

## **6 EMEA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA**

6.1 Astellas Pharma

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 Eli Lilly

6.2.1 Company Basic Information, Manufacturing Base and Competitors

6.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 GlaxoSmithKline

6.3.1 Company Basic Information, Manufacturing Base and Competitors

6.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

6.4 Sanofi

6.4.1 Company Basic Information, Manufacturing Base and Competitors

6.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

6.5 ADC Therapeutics

6.5.1 Company Basic Information, Manufacturing Base and Competitors

6.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview



## 6.6 Advaxis

6.6.1 Company Basic Information, Manufacturing Base and Competitors

6.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

## 6.7 Agennix

6.7.1 Company Basic Information, Manufacturing Base and Competitors

6.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Main Business/Business Overview

## 6.8 ANI Pharmaceuticals

6.8.1 Company Basic Information, Manufacturing Base and Competitors

6.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification

6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.8.4 Main Business/Business Overview

## 6.9 BHR Pharma

6.9.1 Company Basic Information, Manufacturing Base and Competitors

6.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification

6.9.2.1 Product A

6.9.2.2 Product B

6.9.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.9.4 Main Business/Business Overview

## 6.10 Bristol-Myers Squibb

6.10.1 Company Basic Information, Manufacturing Base and Competitors

6.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and

## Specification

6.10.2.1 Product A

6.10.2.2 Product B

6.10.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.10.4 Main Business/Business Overview

6.11 Boehringer Ingelheim

6.12 Dendreo

6.13 Endo Pharmaceuticals

## **7 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MANUFACTURING COST ANALYSIS**

7.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

## **8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS**

8.1 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturers in 2016

8.4 Downstream Buyers

## **9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS**

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

- 9.2.1 Pricing Strategy
- 9.2.2 Brand Strategy
- 9.2.3 Target Client
- 9.3 Distributors/Traders List

## **10 MARKET EFFECT FACTORS ANALYSIS**

- 10.1 Technology Progress/Risk
  - 10.1.1 Substitutes Threat
  - 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change

## **11 EMEA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET FORECAST (2017-2022)**

- 11.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Price Forecast (2017-2022)
  - 11.1.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate Forecast (2017-2022)
  - 11.1.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate Forecast (2017-2022)
  - 11.1.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Price and Trend Forecast (2017-2022)
- 11.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.4 Middle Eastt Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.5 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.6 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2017-2022)
- 11.7 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2017-2022)

## **12 RESEARCH FINDINGS AND CONCLUSION**

## **13 APPENDIX**

### 13.1 Methodology/Research Approach

#### 13.1.1 Research Programs/Design

#### 13.1.2 Market Size Estimation

#### 13.1.3 Market Breakdown and Data Triangulation

### 13.2 Data Source

#### 13.2.1 Secondary Sources

#### 13.2.2 Primary Sources

### 13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

## List Of Tables

### LIST OF TABLES AND FIGURES

- Figure Product Picture of Benign Prostatic Hyperplasia (BPH) Drugs
- Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) by Type (2012-2022)
- Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Market Share by Type (Product Category) in 2016
- Figure Alpha-blocker Product Picture
- Figure Phosphodiesterase type-5 inhibitors Product Picture
- Figure 5-alpha-Reductase inhibitors Product Picture
- Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) by Application (2012-2022)
- Figure EMEA Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2016
- Figure Clinical medicine Examples
- Figure Scientific research Examples
- Figure Others Examples
- Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Million USD) by Region (2012-2022)
- Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Status and Forecast by Countries
- Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Status and Forecast by Countries
- Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Status and Forecast by Countries
- Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2012-2022)
- Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Major Players Product Sales Volume (MT) (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) of Major Players (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players (2012-2017)

Figure 2016 Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players

Figure 2017 Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Players (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players (2012-2017)

Table 2016 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players

Table 2017 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sale Price (USD/Kg) by Players (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Market Share by Type (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2012-2017)

Figure Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2012-2017)

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2016

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sale Price (USD/Kg) by Type (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Market Share by Application (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2012-2017)

Figure Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application

(2012-2017)

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2016

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Market Share by Region (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Region (2012-2017)

Figure Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2012-2017)

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2016

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Region (2012-2017)

Figure Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2012-2017)

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Regions in 2016

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price (USD/Kg) by Region (2012-2017)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2017)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Type (2012-2017)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type (2012-2017)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2016

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Application (2012-2017)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2012-2017)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2016

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Countries (2012-2017)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by



Countries (2012-2017)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2012-2017)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2016

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Countries (2012-2017)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2016

Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure France Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Benelux Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2017)

Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Type (2012-2017)

Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type (2012-2017)

Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type (2012-2017)

Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Applications (2012-2017)

Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Applications (2012-2017)



Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2016

Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) by Countries (2012-2017)

Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Market Share by Countries (2012-2017)

Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Market Share by Countries in 2016

Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Countries (2012-2017)

Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2016

Figure Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Israel Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Iran Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2017)

Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Type (2012-2017)

Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2012-2017)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2012-2017)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2016

Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Application (2012-2017)

Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by

Application (2012-2017)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2012-2017)

Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) by Countries (2012-2017)

Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2012-2017)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2012-2017)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2016

Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Countries (2012-2017)

Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2016

Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Algeria Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)

Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)

Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)

Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)

Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate

(2012-2017)

Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Agennix Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)

Table ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)

Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)

Table BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)

Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)

Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table Dendreo Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs

Figure Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

Figure Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis

Table Raw Materials Sources of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturers in 2016

Table Major Buyers of Benign Prostatic Hyperplasia (BPH) Drugs

Table Distributors/Traders List

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate Forecast (2017-2022)

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate Forecast (2017-2022)

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Kg) and Trend Forecast (2017-2022)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Region (2017-2022)

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2017-2022)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Forecast by Region (2017-2022)

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Region (2017-2022)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Countries (2017-2022)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)



Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Countries (2017-2022)

Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Countries (2017-2022)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Type (2017-2022)

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2017-2022)

Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Application (2017-2022)

Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2017-2022)

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

## I would like to order

Product name: EMEA (Europe, Middle East and Africa) Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017

Product link: <https://marketpublishers.com/r/E415DA13AAAPEN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E415DA13AAAPEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

